Retatrutide is an investigational GLP-1, GIP, and glucagon triple receptor agonist not yet authorised by the MHRA, EMA, or FDA
At TrimRx, our mission is to help you embrace a healthier lifestyle through science, empathy, and a transparent, personalized approach to sustainable weight loss
Available strengths range from 0.25 mg up to 2.5 mg weekly, with total peptide content adjusted accordingly (weekly dose 4)
Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes
The FDA reports that the distribution of Wegovy, in various dosages, has been temporarily paused
Pew Research Center conducted this study to understand Americans views of drugs being used for weight loss